Literature DB >> 11878817

Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism.

Kenji Kashiwagi1, Naoaki Kanai, Takayuki Tsuchida, Michihiro Suzuki, Yoko Iizuka, Yuko Tanaka, Shigeo Tsukahara.   

Abstract

The pharmacological differences between isopropyl unoprostone (referred to as unoprostone) and latanoprost, concerning their induction of endogenous prostaglandin E(2)(PGE(2)) and affinity to a human prostaglandin transporter (PGT), were investigated. Freshly dissected bovine iris tissues were incubated with major intraocular metabolites of unoprostone, M1 and M2, acid of latanoprost, or PGF(2 alpha), and PGE(2)induction was measured. Affinities of M1, M2, latanoprost, acid of latanoprost, and PGF(2 alpha)to PGT molecule were measured using PGT-cDNA transfected HeLa cells by an isotopic influx assay.(3)H-unoprostone was incubated with freshly prepared serum, aqueous humor, or frozen stored fetal bovine serum (FBS), and the radioactivity of supernatants was measured to investigate their metabolism of(3)H-unoprostone.M2, acid of latanoprost, and PGF(2 alpha)significantly increased a release of PGE(2)compared with the control. 10 microM indomethacin completely inhibited PGE(2)induction by acid of latanoprost and PGF(2 alpha), while 100 microM indomethacin was required to inhibit PGE(2)induction completely by M1 and M2. Unoprostone, M1, M2, and latanoprost showed little affinity to PGT, while acid of latanoprost had an affinity to PGT. Freshly prepared serum and aqueous humor metabolized unoprostone, but frozen stored FBS did not. The release of endogenous PGE(2)may play an important role of action by means of PG analogs, and differences in indomethacin-related inhibition of PGE(2)release and in affinities to PGT may in part cause their different actions. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11878817     DOI: 10.1006/exer.2001.1104

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  8 in total

1.  Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension.

Authors:  T Chiba; K Kashiwagi; N Chiba; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

2.  Neuroprotective effect of latanoprost on rat retinal ganglion cells.

Authors:  Hideyo Kudo; Toru Nakazawa; Masahiko Shimura; Hidetoshi Takahashi; Nobuo Fuse; Kenji Kashiwagi; Makoto Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

3.  Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats.

Authors:  Jessica E McDonald; Julie A Kiland; Paul L Kaufman; Ellison Bentley; N Matthew Ellinwood; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2015-07-16       Impact factor: 1.644

Review 4.  Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

5.  The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.

Authors:  Takashi Ota; Makoto Aihara; Tadashiro Saeki; Shuh Narumiya; Makoto Araie
Journal:  Br J Ophthalmol       Date:  2006-11-23       Impact factor: 4.638

6.  Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost.

Authors:  K Kashiwagi; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

7.  Expression and localization of prostaglandin transporter in Alzheimer disease brains and age-matched controls.

Authors:  Koyi Choi; Hean Zhuang; Barbara Crain; Sylvain Doré
Journal:  J Neuroimmunol       Date:  2008-03-18       Impact factor: 3.478

Review 8.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.